Company newsREGN
Explain this story: Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion
Regeneron Pharmaceuticals (REGN) stock appears potentially undervalued, trading at a P/E ratio close to its sector average but below its peer group, according to Simply Wall St. This assessment comes despite a recent expansion of its alliance with Sanofi, which brings a US$1 billion upfront payment and potential milestone payments. The analysis suggests that Regeneron's current earnings multiple is at a discount to what a Fair Ratio benchmark indicates, factoring in the company's margins, growth profile, size, and risk.
OtherSimply Wall StreetSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Regeneron Pharmaceuticals (REGN) stock appears potentially undervalued, trading at a P/E ratio close to its sector average but below its peer group, according to Simply Wall St. This assessment comes despite a recent expansion of its alliance with Sanofi, which brings a US$1 billion upfront payment and potential milestone payments. The analysis suggests that Regeneron's current earnings multiple is at a discount to what a Fair Ratio benchmark indicates, factoring in the company's margins, growth profile, size, and risk.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.